PDGFB and sarcoma: Apart from GIST, only a minority of sarcomas harbor a driver targetable genetic aberration, including ALK fusion in IMT targeted with crizotinib and other TKIs [60], PDGFb fusion in dermatofibrosarcoma protuberans (DFSPs) targeted with imatinib [61], and CDK4 amplification in WDLPS and DDLPS targeted with CDK4/6 inhibitors [62].